Damora Launches First Clinical Trial for DMR-001, a Potential Best-in-Class Blood Cancer Therapy
DMRA has more than doubled off its 52-week low of $2.45.
Summary
Damora has dosed the first patient in its Phase 1/1b CLARITY-101 trial of DMR-001, a long-acting antibody targeting mutant calreticulin in essential thrombocythemia and myelofibrosis. The trial uses an adaptive Bayesian design with a starting dose of 100 mg monthly, aiming to rapidly identify a recommended dose. Preclinical data showed up to 30-fold greater potency and a five-fold longer half-life than a reference antibody, supporting best-in-class potential. This is the company's first clinical program, moving it from preclinical to clinical stage. Initial data are expected in mid-2027, which will be the next major catalyst. The strong cash runway into 2029, noted in the May 10-Q, provides ample funding through these readouts.
At the time of this announcement, DMRA was trading at $30.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.45 to $38.33. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.